Actively Recruiting
Evaluating Oral BAY2927088 Sevabertinib in Adults With Metastatic or Unresectable Solid Tumors Having HER2-Activating Mutations
Led by Bayer · Updated on 2026-11-04
111
Participants Needed
54
Research Sites
38 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well BAY2927088 sevabertinib works and how safe it is for adults with solid tumors that have HER2-activating mutations. The study focuses on tumors in the colon, rectum, uterus, cervix, breast, bladder, biliary tract, and other solid tumors, excluding advanced non-small cell lung cancer NSCLC. The abnormal HER2 protein in cancer cells may cause increased growth, and this treatment aims to block that protein. Participants will take 20 mg of BAY2927088 tablets by mouth twice daily in 3-week cycles. They will continue treatment until their cancer worsens, they face medical issues, or choose to leave the study. This is a single-group, open-label Phase 2 study involving about 111 adult participants with metastatic or unresectable tumors. During the trial, doctors will monitor participants using imaging scans to track cancer spread and heart health assessments including echocardiograms, cardiac MRI, and electrocardiograms. Blood and urine samples, physical exams, and questionnaires about health and symptoms will also be collected. The main outcome measured is the objective response rate according to RECIST 1.1 criteria, with follow-up up to about 3 years.
CONDITIONS
Brief Title
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here